Physician profile
Alexander Doan
NPI 1003859661
$32,590.97
in general payments reported to CMS, 2019-2025
61 companies · $5,595 in 2025
The $5,595 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,145 · 2020: $2,887 · 2021: $4,512 · 2022: $5,165 · 2023: $4,442 · 2024: $4,846 · 2025: $5,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,521.38 |
| Education | $361.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,576.50 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $3,003.82 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Amgen INC. | $2,896.41 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $1,640.63 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $1,484.71 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $1,458.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,384.74 | 2019-2022 | |
| Corcept Therapeutics | $1,359.53 | 2019-2025 | Korlym |
| Opko Pharmaceuticals, LLC | $1,155.86 | 2019-2025 | Rayaldee |
| Amarin Pharma, INC. | $1,127.86 | 2019-2023 | |
| Vifor Pharma, INC. | $849.90 | 2019-2025 | Veltassa, Korsuva |
| Ani Pharmaceuticals, INC. | $798.05 | 2022-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $757.43 | 2019-2025 | Velphoro, Velphoro |
| Sanofi-Aventis U.S. LLC | $723.20 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $716.76 | 2019-2025 | Verquvo |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.